前列腺癌放疗后晚期毒性耐受剂量的系统综述:QUANTEC后更新
该系统综述检索2010年1月1日后PubMed英文全文,纳入33项研究(每症状域36至746例),汇总外照射 alone 及含近距离治疗的前列腺癌放疗后晚期胃肠、泌尿及性功能症状的剂量体积耐受阈值,共识别17种症状的更新耐受剂量,并为5种胃肠症状建立汇总曲线。
要点
- 外照射 alone 后胃肠毒性耐受阈值最多(97个),泌尿8个,性功能1个。
- 5种胃肠症状(排便急迫、腹泻、大便失禁、直肠炎、直肠出血)的耐受阈值可汇总拟合曲线(R²=0.98)。
- 泌尿与性功能毒性耐受阈值稀少,作者支持进一步研究及数据共享。
核心结论
- QUANTEC后更新了17种胃肠、泌尿或性功能症状的剂量体积耐受阈值。
- 外照射 alone 后5种胃肠症状的耐受阈值可用一条剂量体积直方图曲线描述(R²=0.98)。
- 使用该曲线下界限制外照射 alone 治疗可能限制总体胃肠毒性,但需前瞻性探索。
- 外照射 alone 及含或不含外照射的近距离治疗后泌尿和性功能毒性耐受阈值稀少,支持进一步研究及数据共享以阐明剂量体积关系。
研究设计与样本
- 系统综述,检索2010年1月1日后PubMed英文全文,方案注册于PROSPERO(CRD42016042464)。
- 纳入随机对照试验、病例对照研究或队列研究,要求报告前列腺癌原发放疗后≥3个月晚期 distinct 症状的耐受剂量且样本量>30例。
- 共纳入33项研究,每症状域包含36至746例患者。
主要发现
- 外照射 alone 后胃肠毒性97个阈值、泌尿8个阈值、性功能1个阈值;含近距离治疗(±外照射)后胃肠14个、泌尿4个、性功能2个阈值。
- 上述胃肠症状的阈值主要涉及直肠,覆盖低剂量(10 Gy ≤ EQD2₃ ≤ 50 Gy)和高剂量(55 Gy ≤ EQD2₃ ≤ 78 Gy)范围。
- 含近距离治疗(±外照射)的耐受阈值主要针对胃肠毒性,其中直肠出血相关DVH阈值最多(5个)。
关键数值与推荐
- 耐受阈值定义为研究中症状组与无症状组之间差异有统计学意义(P ≤ .05)的剂量体积直方图截断点。
- 所有DVH阈值转换为2 Gy分次等效剂量(EQD2α/β)并以线性或线性二次函数拟合(拟合优度R²)。
临床怎么用
- 作者认为,使用外照射 alone 后5种胃肠症状汇总曲线的下界限制治疗可能限制总体胃肠毒性,但需前瞻性探索。
- 作者支持进一步研究及数据共享以阐明泌尿和性功能毒性的剂量体积关系。
局限性
- 外照射 alone 后泌尿和性功能毒性以及含近距离治疗后的剂量体积耐受阈值稀少。
- 使用汇总曲线下界限制外照射 alone 治疗以限制总体胃肠毒性的推断需前瞻性探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aims of this study were to systematically review tolerance doses for late distinct gastrointestinal (GI), genitourinary (GU), and sexual dysfunction (SD) symptoms after external beam radiation therapy (EBRT) alone and treatments involving brachytherapy (BT) for prostate cancer after Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) and ultimately to perform quantitative syntheses of identified dose/volume tolerances represented by dose-volume histogram (DVH) thresholds, that is, statistically significant (P ≤ .05) cutoff points between symptomatic and asymptomatic patients in a certain study. METHODS AND MATERIALS: PubMed was scrutinized for full-text articles in English after QUANTEC (January 1, 2010). The inclusion criteria were randomized controlled trials, case-control studies, or cohort studies with tolerance doses for late distinct symptoms ≥3 months after primary radiation therapy for prostate cancer (N > 30). All DVH thresholds were converted into equivalent doses in 2-Gy fractions (EQD2α/β) and were fitted with a linear or linear-quadratic function (goodness of fit, R2). The review was registered on PROSPERO (CRD42016042464). RESULTS: From 33 identified studies, which included 36 to 746 patients per symptom domain, the majority of dose/volume tolerances were derived for GI toxicity after EBRT alone (GI, 97 thresholds; GU, 8 thresholds; SD, 1 threshold). For 5 symptoms (defecation urgency, diarrhea, fecal incontinence, proctitis, and rectal bleeding), relationships between dose/volume tolerances across studies (R2 = 0.93 [0.82-1.00]), and across symptoms, leading to a curve for overall GI toxicity (R2 = 0.98), could be determined. For these symptoms, mainly rectal thresholds were found throughout low and high doses (10 Gy ≤ equivalent dose in 2-Gy fractions using α/β = 3Gy (EQD23) ≤ 50 Gy and 55 Gy ≤ EQD23 ≤ 78 Gy, respectively). For BT with or without EBRT, dose/volume tolerances were also mainly identified for GI toxicity (GI, 14 thresholds; GU, 4 thresholds; SD, 2 thresholds) with the largest number of DVH thresholds concerning rectal bleeding (5 thresholds). CONCLUSIONS: Updated dose/volume tolerances after QUANTEC were found for 17 GI, GU, or SD symptoms. A DVH curve described the relationship between dose/volume tolerances across 5 GI symptoms after EBRT alone. Restricting treatments for EBRT alone using the lower boundaries of this curve is likely to limit overall GI toxicity, but this should be explored prospectively. Dose/volume tolerances for GU and SD toxicity after EBRT alone and after BT with or without EBRT were scarce and support further research including data-sharing initiatives to untangle the dose/volume relationships for these symptoms.
引用
- Olsson CE, Jackson A, Deasy JO, et al. A Systematic Post-QUANTEC Review of Tolerance Doses for Late Toxicity After Prostate Cancer Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 30125635. doi:10.1016/j.ijrobp.2018.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。